EC
LYEL icon

EntryPoint Capital’s Lyell Immunopharma LYEL Stock Holding History

EntryPoint Capital’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Buy
+19,410
New +$351K 0.07% 591
2024
Q4 		– Sell
-10,400
Closed -$287K – 867
2024
Q3 		$287K Buy
10,400
+1,113
+12% +$32.7K 0.16% 265
2024
Q2 		$269K Buy
9,287
+7,951
+595% +$379K 0.13% 239
2024
Q1 		$59.6K Sell
1,336
-1,946
-59% -$83.3K 0.05% 670
2023
Q4 		$127K Buy
+3,282
New +$118K 0.12% 260

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

EntryPoint Capital's LYEL Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 19,410 shares worth $273K. The stake represents 0.07% of the portfolio and ranks #591 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in LYEL as recently as Q3 2024.

EntryPoint Capital first reported a position in LYEL in Q4 2023 and has held it in 5 quarters since. The position peaked at $287K in Q3 2024. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • EntryPoint Capital held 19,410 shares of Lyell Immunopharma worth $273K as of Q2 2026.
  • Lyell Immunopharma was a new EntryPoint Capital position in Q2 2026.
  • Lyell Immunopharma made up 0.07% of EntryPoint Capital's portfolio in Q2 2026, its #591 holding.
  • EntryPoint Capital first reported a position in Lyell Immunopharma in Q4 2023 and has held it in 5 quarters since.
  • EntryPoint Capital's Lyell Immunopharma position peaked at $287K in Q3 2024.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.